Neoadjuvant Immunotherapy Clinical Trials

18 clinical trials for Neoadjuvant Immunotherapy across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study — RECRUITING
• Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) — RECRUITING · PHASE2
• Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab — RECRUITING · PHASE2
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer — RECRUITING
• Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC — RECRUITING · PHASE2
• The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer — RECRUITING
• Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery — RECRUITING · PHASE2
• Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC — NOT_YET_RECRUITING · PHASE2
• QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk — NOT_YET_RECRUITING · PHASE2
• Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC — NOT_YET_RECRUITING · PHASE2
• A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC — NOT_YET_RECRUITING · PHASE2
• Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer — WITHDRAWN
• Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer — OTHER
• Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma — OTHER · PHASE1
• Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma — NOT_YET_RECRUITING · PHASE3
• CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy — OTHER
• PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer — OTHER · PHASE2

Refine this search